You are not allowed to view links.
Register or LoginREVISED FINAL REPORT
Submitted to:
Multidisciplinary Association for Psychedelic Studies (MAPS) And California NORML
Prepared by:
Chemic Laboratories, Inc.
Reissued: April 15, 2003
April 8, 2003
Resumen:
The findings show substantial reduction (about 99%) in certain toxins in the vapor as compared to marijuana smoke, and substantial amounts of cannabinoids produced by the vaporizer. The results could hardly have been better. This report has been submitted to FDA as part of Dr. Donald Abrams’ IND application to study subjective effects and cannabinoid blood levels in subjects who both smoke marijuana and then at a later time inhale marijuana vapors. We should hear from FDA in early May about what additional information, if any, it needs to have before deciding if the vaporizer can be used in a clinical trial. [/url]
